165385-89-7

Basic information

• Product Name: 6-METHYL-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
• Synonyms: 6-METHYL-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE;2-AMino-6-Methyl-4-(trifluoroMethyl)pyridine;(6-Methyl-4-trifluoroMethylpyridin-2-yl)aMine;6-Methyl-4-(trifluoroMethyl)-2-pyridinaMine
• CAS NO: 165385-89-7
• Molecular Formula: C7H7F3N2
• Molecular Weight: 176.14
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates;Amines, Aromatics, Heterocycles, Intermediates
• Mol File: 165385-89-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-METHYL-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYL-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE(165385-89-7)
• EPA Substance Registry System: 6-METHYL-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE(165385-89-7)

Safety Data

• Hazardous Substances Data: 165385-89-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-methyl-4-(trifluoromethyl)pyridin-2-amine is used as a key intermediate compound for the synthesis of tetrameric fructose-1,6-bisphosphatase inhibitors. These inhibitors play a crucial role in regulating glucose metabolism and are being investigated for their potential therapeutic applications in treating type 2 diabetes and other metabolic disorders.
Additionally, 6-methyl-4-(trifluoromethyl)pyridin-2-amine is utilized in the development of other pharmaceutical agents, showcasing its versatility and importance in the synthesis of various drugs. Its unique chemical structure allows for the creation of novel compounds with potential therapeutic benefits, making it a valuable asset in the field of medicinal chemistry.

Upstream product

• 22123-14-4 2-chloro-6-methyl-4-(trifluoromethyl)pyridine 
• 39890-98-7 2,6-dichloro-4-(trifluoromethyl)pyridine 
• 823-96-1 Trimethylboroxine 
• 34486-23-2 6-chloro-4-(trifluoromethyl)pyridin-2-amine 

Relevant articles and documents

4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain H-APPAMP compounds (referred to herein as "H-APPAMP compounds") that, inter alia, inhibit cyclin-dependent protein kinases (CDKs), especially CDK12 and/or CDK13, and are selective, for example, for CDK12 and/or CDK13 as compared to CDK7. In addition to selectively inhibiting CDK12 and/or CDK13, the compounds also act as selective Cyclin K degraders thereby removing the key signaling mechanism required for CDK12 and/or CDK13 activation; this confers additional cellular potency and selectivity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK, especially CDK12 and/or CDK13; and to treat disorders including: disorders that are associated with CDK, especially CDK12 and/or CDK13; disorders that result from an inappropriate activity of a CDK, especially CDK12 and/or CDK13; disorders that are associated with CDK mutation, especially CDK12 and/or CDK13mutation; disorders that are associated with CDK overexpression, especially CDK12 and/or CDK13 overexpression; disorders that are associated with upstream pathway activation of CDK, especially CDK12 and/or CDK13; disorders that are ameliorated by the inhibition of CDK, especially CDK12 and/or CDK13; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); autoimmune disorders (including rheumatoid arthritis); and disorders caused by dysfunction of translation in cells (including muscular dystrophy). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti estrogen, an anti-androgen, a Her2 blocker, a cytotoxic chemotherapeutic agent, an agent stimulating the immune system, a checkpoint inhibitor, a DMA repair inhibitor, etc.

multi-links class PI3K inhibitors (by machine translation)

The invention belongs to the field of medical technology, in particular of formula (I) shown in multi-links class of PI3K inhibitors, its stereoisomers or its pharmaceutically acceptable salt thereof, wherein the R 1, R 2, R 3, R 4 or R 5 as defined in the specification; the invention also relates to methods of preparing such compounds, pharmaceutical compositions of these compounds in the preparation and treatment and/or prevention of proliferative diseases of the use of the medicament. (by machine translation)

Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase

A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase.

NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES

Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.